It is generally thought that the effects of immunotherapy depend on the following three factors: (1) elevated expression of PD-L1 by tumor cells; (2) a higher tumor mutational burden associated with targeting by mutation-associated neoantigen-specific T cells, and (3) greater tumor infiltration by TILs. The gene discussed is CD274; the disease is neoplasm.